Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Oral LBH589 in Refractory Cutaneous T-Cell Lymphoma
2006-000880-27Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Novartis. Primary endpoint: Efficacy response rate by mSWAT. Started Nov 2006; status: completed.
02
Drugs
panobinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2006-000880-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000880-27.